Accessibility Statement Skip Navigation
  • PRNewswire.com
  • Resources
  • +91 22-69790010
  • Client Login
  • Send a Release
PR Newswire: news distribution, targeting and monitoring
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please use Advanced Search to search all press releases.
  • Overview
  • Distribution
  • Guaranteed Paid Placement
  • SocialBoost
  • Multichannel Amplification
  • All Products
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • Telephone

    • +91 22-69790010 from 9 AM - 5:30 PM IST

    • Contact
    • Contact

      +91 22-69790010
      from 9 AM - 5:30 PM IST

  • Request More Information
  • Journalists
  • Request More Information
  • Journalists
  • Overview
  • Distribution by PR Newswire
  • Guaranteed Paid Placement
  • SocialBoost
  • Multichannel Amplification
  • All Products
  • Request More Information
  • Journalists
  • Request More Information
  • Journalists

Johnson & Johnson Innovation Announces Launch of Shanghai Lung Cancer Innovation QuickFire Challenge
  • USA - English
  • Latin America - español
  • Brazil - Português
  • USA - Deutsch
  • USA - español
  • USA - Français


News provided by

Johnson & Johnson Innovation

14 Jun, 2018, 11:30 IST

Share this article

Share toX

Share this article

Share toX

SHANGHAI, June 14, 2018 /PRNewswire/ --  Johnson & Johnson Innovation, Division of Johnson & Johnson (China) Investment Ltd., today announced the launch of the Shanghai Lung Cancer Innovation QuickFire Challenge to identify new solutions for lung health and to combat lung cancer in China and around the world. Avrum Spira, Global Head, Lung Cancer Initiative, Johnson & Johnson, and Melinda Richter, Global Head, Johnson & Johnson Innovation, JLABS, made the announcement at CES Asia in Shanghai, China.

The Shanghai Lung Cancer Innovation QuickFire Challenge seeks to identify cutting-edge, early-stage innovation from around the world that addresses all stages of lung health. The competition will be open to entrepreneurs, academicians, biotech researchers and start-up companies from around the world with innovative ideas that have the potential to prevent, intercept or cure lung cancer, improving the health and wellbeing of millions of people in China and around the world.

Up to three innovators with the best idea, technology, or solution across pharmaceuticals, consumer, medical devices, global public health, and/or health technologies will be awarded up to US$750,000 (approximately RMB4,775,850) in total grants; one-year of residency at JLABS @ Shanghai, including a laboratory bench, workstation and access to the JLABS community; and mentorship and coaching from Johnson & Johnson Innovation, the Janssen Pharmaceutical Companies of Johnson & Johnson, and/or affiliate experts. The winners will be announced in Spring 2019 at the grand opening of the JLABS @ Shanghai in Shanghai, China.

"We are excited to bring the QuickFire Challenge to China for the first time. China is playing an increasing role in the global healthcare innovation system by leveraging competitive advantages including talent, scale, speed, financing options and an enabling policy environment," said Melinda Richter, Global Head of Johnson & Johnson Innovation, JLABS. "In line with the vision of the new and upcoming JLABS @ Shanghai, where the winners will be offered residency, we believe a good idea can come from anywhere, and it's our goal to find new and innovative technologies that provide solutions to people globally. Working together, we can spark the next great idea to change the trajectory of health."

The QuickFire Challenge welcomes submissions from June 14 to September 14, 2018. For more information about the Shanghai Lung Cancer Innovation QuickFire Challenge (including the terms and conditions of entry), please visit: http://jlabs.tv/lungs

Related Links

http://jlabs.tv/lungs

Modal title

Contact PR Newswire

  • +91 22-69790010

Global Sites

  • APAC
  • APAC - Traditional Chinese
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany

 

  • India
  • Indonesia
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland

 

  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921
Global Sites
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States
+91 (0) 22 6169 6000
from 9 AM - 5:30 PM IST
  • Terms of Use
  • Privacy Policy
  • GDPR
  • Information Security Policy
  • Site Map
  • Cookie Settings
Copyright © 2025 Cision US Inc.